Evolving epidemiology and antimicrobial resistance in spontaneous bacterial peritonitis: A two-year observational study

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Piroth, Lionel ^a,b   Pechinot, André ^a,b   Di Martino, Vincent ^c   Hansmann, Yves ^d   Putot, Alain ^a   Patry, Isabelle ^c   Hadou, Tahar ^e   Jaulhac, Benoit ^d   Chirouze, Catherine ^c   Rabaud, Christian ^e   Lozniewski, Alain ^e   Neuwirth, Catherine ^a,b   Chavanet, Pascal ^a,b   Minello, Anne ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c UNIVERSITY HOSPITAL OF BESANÇON   (France)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Antibiotic susceptibility; Bacterascites; Epidemiology; Resistance; Spontaneous bacterial peritonitis

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; ASCITES FLUID; BACTERIAL PERITONITIS; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SURVEILLANCE; ENTEROBACTER; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; INTESTINE FLORA; KLEBSIELLA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NEUTROPHIL COUNT; NONHUMAN; OBSERVATIONAL STUDY; PROTEIN CONTENT; SERRATIA; SPECIES DISTRIBUTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; UNIVERSITY HOSPITAL; AGED; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTIONS; CLINICAL TRIAL; CROSS INFECTION; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOGENICITY; PERITONITIS; TREATMENT OUTCOME;

AGED; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ASCITIC FLUID; BACTERIAL INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PERITONITIS; TREATMENT OUTCOME;

EID: 84902383338     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-287     Document Type: Article

References (24)

1. Thuluvath PJ, Morss S, Thompson R. Spontaneous bacterial peritonitis-in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998. Am J Gastroenterol 2001, 96:1232-1236.
2. Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, Inadomi JM. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. Int Ascites Club J Hepatol 2000, 32:142-153.
3. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008, 28:26-42. 10.1055/s-2008-1040319, 18293275.
4. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Gines P, Rodes J. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999, 341:403-409. 10.1056/NEJM199908053410603, 10432325.
5. EASL Clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010, 53:397-417. EASL.
6. Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 2012, 61:297-310. 10.1136/gutjnl-2011-300779, 22147550.
7. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009, 49:2087-2107. 10.1002/hep.22853, 19475696.
8. Song KH, Jeon JH, Park WB, Park SW, Kim HB, Oh MD, Lee HS, Kim NJ, Choe KW. Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case-control study. BMC Infect Dis 2009, 9:41. 10.1186/1471-2334-9-41, 2671512, 19361340.
9. Fernandez J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D, Pavesi M, Sola E, Moreira L, Silva A, Seva-Pereira T, Corradi F, Mensa J, Gines P, Arroyo V. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012, 55:1551-1561. 10.1002/hep.25532, 22183941.
10. Piroth L, Pechinot A, Minello A, Jaulhac B, Patry I, Hadou T, Hansmann Y, Rabaud C, Chavanet P, Neuwirth C. Bacterial epidemiology and antimicrobial resistance in ascitic fluid: a 2-year retrospective study. Scand J Infect Dis 2009, 41:847-851. 10.3109/00365540903244535, 19922067.
11. Chu CM, Chang KY, Liaw YF. Prevalence and prognostic significance of bacterascites in cirrhosis with ascites. Dig Dis Sci 1995, 40:561-565. 10.1007/BF02064369, 7895544.
12. Pleguezuelo M, Benitez JM, Jurado J, Montero JL, De la Mata M. Diagnosis and management of bacterial infections in decompensated cirrhosis. World J Hepatol 2013, 5:16-25. 10.4254/wjh.v5.i1.16, 3562722, 23383362.
13. Pariente EA. Antibiotic treatment of spontaneous bacterial peritonitis: don't forget enterococci!. Gastroenterology 1992, 102:375-376.
14. Lee JH, Yoon JH, Kim BH, Chung GE, Myung SJ, Kim W, Kim YJ, Kim EC, Lee HS. Enterococcus: not an innocent bystander in cirrhotic patients with spontaneous bacterial peritonitis. Eur J Clin Microbiol Infect Dis 2009, 28:21-26. 10.1007/s10096-008-0578-3, 18612666.
15. Thevenot T, Degand T, Grelat N, Elkrief L, Christol C, Moreau R, Henrion J, Cadranel JF, Sheppard F, Bureau C, Di Martino V, Pauwels A. A French national survey on the use of antibiotic prophylaxis in cirrhotic patients. Liver Int 2013, 33:389-397. 10.1111/liv.12093, 23302021.
16. Frances R, Gonzalez-Navajas JM, Zapater P, Munoz C, Cano R, Pascual S, Santana F, Marquez D, Perez-Mateo M, Such J. Translocation of bacterial DNA from Gram-positive microorganisms is associated with a species-specific inflammatory response in serum and ascitic fluid of patients with cirrhosis. Clin Exp Immunol 2007, 150:230-237. 10.1111/j.1365-2249.2007.03494.x, 2219344, 17822441.
17. Ricart E, Soriano G, Novella MT, Ortiz J, Sabat M, Kolle L, Sola-Vera J, Minana J, Dedeu JM, Gomez C, Barrio JL, Guarner C. Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients. J Hepatol 2000, 32:596-602. 10.1016/S0168-8278(00)80221-4, 10782908.
18. Navasa M, Follo A, Llovet JM, Clemente G, Vargas V, Rimola A, Marco F, Guarner C, Forne M, Planas R, Banares R, Castells L, Jimenez D. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996, 111:1011-1017. 10.1016/S0016-5085(96)70069-0, 8831596.
19. Bert F, Andreu M, Durand F, Degos F, Galdbart JO, Moreau R, Branger C, Lambert-Zechovsky N, Valla D. Nosocomial and community-acquired spontaneous bacterial peritonitis: comparative microbiology and therapeutic implications. Eur J Clin Microbiol Infect Dis 2003, 22:10-15.
20. Ducroix JP, Guerlin M, Hary L, Smail A, Denamur E, Eb F, Andrejak M, Baillet J. [Clinical and pharmacokinetic study of ceftriaxone in the treatment of 14 episodes of ascitic fluid infection]. Pathol Biol (Paris) 1988, 36:1007-1010.
21. Grange JD, Gouyette A, Gutmann L, Amiot X, Kitzis MD, Islam S, Acar JF, Jaillon P. Pharmacokinetics of amoxycillin/clavulanic acid in serum and ascitic fluid in cirrhotic patients. J Antimicrob Chemother 1989, 23:605-611. 10.1093/jac/23.4.605, 2745264.
22. Hary L, Andrejak M, Leleu S, Orfila J, Capron JP. The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites. Eur J Clin Pharmacol 1989, 36:613-616. 10.1007/BF00637745, 2776819.
23. Sambatakou H, Giamarellos-Bourboulis EJ, Galanakis N, Giamarellou H. Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. Int J Antimicrob Agents 2001, 18:441-444. 10.1016/S0924-8579(01)00441-1, 11711259.
24. Wise R, Donovan IA, McNulty CA, Waldron R, Andrews JM. Teicoplanin, its pharmacokinetics, blister and peritoneal fluid penetration. J Hosp Infect 1986, 7(Suppl A):47-55.